OpenEvidence deepens oncology push to enhance specialized AI agent, launches new AI model family

OpenEvidence is leveraging a partnership with a top cancer center to bolster its oncology capabilities, adding trusted genomic interpretation expertise to the AI platform already used by millions of clinicians.

Through the partnership, the company will integrate a precision oncology knowledge base directly into its workflows for expanded use by providers. OpenEvidence previewed the partnership exclusively with Fierce Healthcare, referring to the partner as a "nationally leading cancer center," with plans to identify the organization next week.

The partnership brings precision oncology decision support to clinicians nationwide and deepens OpenEvidence's push into cancer care as the company already directly integrates the foundational frameworks of cancer treatment into its medical search engine. The company has a licensing agreement with the National Comprehensive Cancer Network (NCCN) which integrates its evidence-based oncology guidelines into its platform. The company also integrates ASCO Guidelines, figures and flowcharts into its model.

Through its latest partnership with a leading cancer center, OpenEvidence users gain access to expert-curated interpretations of cancer genomic alterations alongside patient-specific context and peer-reviewed evidence, helping clinicians make more informed treatment decisions, according to OpenEvidence executives.